Viewing Study NCT07430202


Ignite Creation Date: 2026-03-26 @ 3:20 PM
Ignite Modification Date: 2026-04-01 @ 2:18 AM
Study NCT ID: NCT07430202
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-02-24
First Post: 2026-02-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module